Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Clinical trial NCT03011034 · COMPLETED
Trial details
- NCT number
- NCT03011034
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-14
- Primary completion
- 2019-01-23
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.